Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Increasing evidence that the risks of rhAPC may outweigh its benefits.

Eichacker PQ, Natanson C.

Intensive Care Med. 2007 Mar;33(3):396-9. Epub 2007 Feb 15. No abstract available.

PMID:
17325833
2.

Risks and benefits of activated protein C treatment for severe sepsis.

Warren HS, Suffredini AF, Eichacker PQ, Munford RS.

N Engl J Med. 2002 Sep 26;347(13):1027-30. No abstract available.

PMID:
12324562
3.

Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

Plataki M, Vaporidi K, Georgopoulos D.

Intensive Care Med. 2007 Aug;33(8):1485-6; author reply 1489. Epub 2007 Jun 12. No abstract available.

PMID:
17563880
4.

Recombinant human activated protein C, package labeling, and hemorrhage risks.

Sweeney DA, Natanson C, Eichacker PQ.

Crit Care Med. 2009 Jan;37(1):327-9. doi: 10.1097/CCM.0b013e3181935102. No abstract available.

PMID:
19112285
5.

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C.

Crit Care Med. 2005 Oct;33(10):2426-8. No abstract available.

PMID:
16215410
6.

Adverse events and clinical outcome associated with drotrecogin alfa-activated: a single-center experience of 498 patients over 8 years.

Boyle A, McKenzie C, Yassin S, McLuckie A, Wyncoll D.

J Crit Care. 2012 Jun;27(3):320.e7-12. doi: 10.1016/j.jcrc.2011.07.004. Epub 2011 Dec 14.

PMID:
22172792
7.

[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].

Rustige J.

Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1698; author reply 1699-70. German. No abstract available.

PMID:
15273923
8.

[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].

Heslet L, Nielsen JD, Schierbeck J, Andersen JS.

Ugeskr Laeger. 2004 Mar 8;166(11):997-1002. Review. Danish. No abstract available.

PMID:
15049234
9.

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Kanji S, Perreault MM, Chant C, Williamson D, Burry L.

Intensive Care Med. 2007 Mar;33(3):517-23. Epub 2007 Feb 15.

PMID:
17325837
10.

Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial.

Farmer JC.

Crit Care Med. 2005 Oct;33(10):2428-31. No abstract available.

PMID:
16215411
11.
12.

Drotrecogin alfa: excess mortality in the least severely ill patients.

[No authors listed]

Prescrire Int. 2005 Aug;14(78):145. No abstract available.

PMID:
16108104
14.

Activated protein C: do more survive?

Macias WL.

Intensive Care Med. 2006 Apr;32(4):605-7; author reply 610-2. Epub 2006 Mar 1. No abstract available.

PMID:
16508756
15.

Activated protein C: do more survive?

Ridley S.

Intensive Care Med. 2006 Apr;32(4):608; author reply 610-2. Epub 2006 Mar 1. No abstract available.

PMID:
16508755
16.

[Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].

Girbes AR, Polderman KH, Beishuizen A, van Zanten AR, Schultz MJ.

Ned Tijdschr Geneeskd. 2006 Jun 3;150(22):1265-6; author reply 1266. Dutch. No abstract available.

PMID:
16796179
17.

Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.

de Pont AC, Bakx R, Boermeester MA, Schultz MJ.

Surgery. 2007 Jun;141(6):828-9. No abstract available.

PMID:
17560262
18.

Recombinant human activated protein C sentenced to the death of a thousand cuts?

O'Brien JM.

Crit Care Med. 2007 Jun;35(6):1609-10. No abstract available.

PMID:
17522532
19.

Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.

Carlet J.

Crit Care Med. 2006 Feb;34(2):525-9. No abstract available.

PMID:
16424736
20.

Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.

Gentry CA, Gross KB, Sud B, Drevets DA.

Crit Care Med. 2009 Jan;37(1):19-25. doi: 10.1097/CCM.0b013e318192843b.

PMID:
19050637
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk